The β3-Adrenergic System and β3-Adrenergic Agonists

Reviews in Endocrine and Metabolic Disorders

Volumn 2, Issue 4, 2001, Pages 385-393

  Arch, Jonathan R S ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

Author keywords

3 adrenergic; 3 adrenoceptor agonists; 4 adrenoceptor; Diabetes; Obesity; Thermogenesis

Indexed keywords

ADRENERGIC BETA AGONISTS; BETA 3 ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; RECEPTORS, ADRENERGIC, BETA 3;

CHEMISTRY; DRUG EFFECT; GENETICS; HUMAN; PHYSIOLOGY; REVIEW;

ADRENERGIC BETA-AGONISTS; HUMAN; RECEPTORS, ADRENERGIC, BETA-3;

EID: 0035487557     PISSN: 13899155     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1011852500209     Document Type: Article

References (71)

1. Arch JRS, Piercy V, Thurlby PL, Wilson C, Wilson S. Thermogenic and lipolytic drugs for the treatment of obesity: old ideas and new possibilities. In: Berry EM, Blondheim SH, Eliahou HE, Shafrir E, eds. Recent Advances in Obesity Research. V edn. London: John Libbey, 1987;300-311.
2. 1adrenoceptor agonist in in vivo studies on human thermogenesis and lipid utilization. J Appl Physiol 1999;87:977-981.
3. Amoroso P, Wilson SR, Moxham J, Ponte J. Acute effects of inhaled salbutamol on the metabolic rate of normal subjects. Thorax 1993;48:882-885.
4. Cawthorne MA, Arch JRS. The search for peripherally acting drugs for the treatment of obesity - a review. Int J Obesity 1982;6:1-10.
5. Astrup A, Breum L, Toubro S, Hein P, Quade F. The effect and safety of an ephedrine/caffeine compound compared to ephedrine, caffeine and placebo in obese subjects on an energy restricted diet: A double blind trial. Int J Obesity 1992;16:269-277.
6. Norregaard J, Jorgensen S, Mikkelsen KL, Tonnesen P, Iversen E, Sorensen T, Soeberg B, Jakobsen HB. The effect of ephedrine plus caffeine on smoking cessation and postcessation weight gain. Clin Pharm Ther 1996;60:679-686.
7. Holloway BR. Selective β-agonists of brown fat and thermogenesis. In: Lardy HA, Stratman FW, eds. Hormones, Thermogenesis, and Obesity. Elsevier Science Publishing Co., Inc., 1989;477-484.
8. 3-adrenoceptor agonist, in the dog: Lack of central effect. Fundament Clin Pharmacol 1999;13:180-186.
9. 3-adrenergic receptor cardiovascular regulation in conscious primates, rats and dogs. J Pharmacol Exp Ther 1996;278:1435-1443.
10. 3-Adrenoceptor agonist-induced increases in lipolysis, metabolic rate, facial flushing, and reflex tachycardia in anesthetized rhesus monkeys. J Pharmacol Exp Ther 2001;297:299-307.
11. 3 adrenergic receptor agonist increases metabolic rate in Rhesus monkeys. J Clin Invest 1998;101:2387-2393.
12. Foster DC, Frydman ML. Nonshivering thermogenesis in the rat. II Measurements of blood flow with microspheres point to brown adipose tissue as the dominant site of the calorigenesis induced by noradrenaline. Can J Physiol Pharmacol 1978;56:110-122.
13. Arch JRS, Ainsworth AT. Thermogenic and antiobesity activity of a novel β-adrenoceptor agonist (BRL 26830A) in mice and rats. Am J Clin Nutr 1983;38:549-558.
14. 3 and atypical β-adrenoceptors. Med Res Rev 1993;13:663-729.
15. Arch JRS, Ainsworth AT, Cawthorne MA, Piercy V, Sennitt MV, Thody VE, Wilson C, Wilson S. Atypical β-adrenoceptor on brown adipocytes as target for anti-obesity drugs. Nature 1984;309:163-165.
16. Wilson C, Wilson S, Piercy V, Sennitt MV, Arch JRS. The rat lipolytic β-adrenoceptor: Studies using novel β-adrenoceptor agonists. Eur J Pharmacol 1984;100:309-319.
17. 3-adrenergic receptor. Science 1989;245:1118-1121.
18. 3-Adrenoceptor. London & New York: Taylor & Francis, 2000;48-76.
19. 3-adrenergic receptor agonist with β1/2-antagonist properties, in healthy male subjects. Obesity Res 1999;7:121S.
20. Kaumann AJ. Four β-adrenoceptor subtypes in the mammalian heart. Trends Pharmacol Sci 1997;18:70-76.
21. 4-adrenoceptor. Br J Pharmacol 1997;122:1244-1250.
22. 1-adrenergic receptor. Am J Physiol 2001;43:E199-E202.
23. Kaumann AJ, Engelhardt S, Hein L, Molenaar P, Lohse M. Abolition of (-)-CGP 12177-evoked cardiostimulation in double β(1)/β(2)-adrenoceptor knockout mice. Obligatory role of β(1)-adrenoceptors for putative β4-adrenoceptor pharmacology. Naunyn-Schmiedeberg's Arch Pharmacol 2001;363:87-93.
24. 3-adrenoceptor agonists of differing selectivities. J Pharmacol Exp Ther 1998;285:1084-1095.
25. 3-adrenoceptor agonist in human right atrial appendage and human white adipocytes. Br J Pharmacol 1999;126:100P.
26. 1-adrenergic receptors. J Pharmacol Exp Ther 2000;294:923-932.
27. 3-adrenergic agonist in lipoatrophic A-ZIP/F-1 mice. Diabetes 2000;49:1910-1916.
28. Tsujii S, Bray GA. A β-3 adrenergic agonist (BRL-37344) decreases food intake. Physiology & Behavior 1998;63:723-728.
29. Bray GA. Reciprocal relation of food intake and sympathetic activity: experimental observations and clinical implications. Int J Obesity 2000;24 (Suppl. 2):S8-S17.
30. Igawa Y, Yamazaki Z, Takeda H, Hayakawa K, Akahane M, Ajisawa Y, Yoneyama T, Nishizawa O, Andersson KE. Functional and molecular biological evidence for a possible beta3-adrenoceptor in the human detrusor muscle. Br J Pharmacol 1999;126:819-825.
31. 3-Adrenoceptors in the cardiovascular system. Trends Pharmacol Sci 2000;21:426-431.
32. Thurlby PL, Ellis RDM. Differences between the effects of noradrenaline and the β-adrenoceptor agonist BRL 28410 in brown adipose tissue and hind limb of the anaesthetized rat. Can J Physiol Pharmacol 1986;64:1111-1114.
33. Lowell BB, Susulic VS, Hamann A, Lawitts JA, Himms-Hagen J, Boyer BB, Kozak LP, Flier JS. Development of obesity in transgenic mice after genetic ablation of brown adipose tissue. Nature 1993;366:740-742.
34. Lean MEJ, Trayhurn P, Murgatroyd PR, Dixon AK. The case for brown adipose tissue function in humans: biochemistry, physiology and computed tomography. In: Berry EM, Blondheim SH, Eliahou HE, Shaffrir E. Recent Advances in Obesity Research. V edn. London: John Libbey, 1987;110-117.
35. Blaak EE, van Baak MA, Kemerink GJ, Pakbiers MTW, Heidendal GAK, Saris WHM. β-adrenergic stimulation of energy expenditure and forearm skeletal muscle metabolism in lean and obese men. Am J Physiol 1994;267:E306-E315.
36. Block BA. Thermogenesis in muscle. Annu Rev Physiol 1994;56:535-577.
37. Astrup A, Bulow J, Madsen J, Christensen NJ. Contribution of BAT and skeletal muscle to thermogenesis induced by ephedrine in man. Am J Physiol 1985;248:E507-E515.
38. Havel RJ, Carlson LA, Ekelund L-G, Holmgren A. Studies on the relation between mobilization of free fatty acids and energy metabolism in man: effects of norepinephrine and nicotinic acid. Metabolism 1964;13:1402-1411.
39. 1-adrenoceptor-mediated thermogenesis in man. Metabolism 1998;47:1462-1467.
40. 3selective agonist-induced effects on energy expenditure, insulin secretion, and food intake. J Biol Chem 1997;272:17686-17693.
41. Wilson S, Thurlby PL, Arch JRS. Substrate supply for thermogenesis induced by the β-adrenoceptor agonist BRL 26830A. Can J Physiol Pharmacol 1986;65:113-119.
42. Ito M, Grujic D, Abel ED, Vidalpuig A, Susulic VS, Lawitts J, Harper ME, Himms-Hagen J, Strosberg AD, Lowell BB. Mice expressing human but not murine β-adrenergic receptors under the control of human gene regulatory elements. Diabetes 1998;47:1464-1471.
43. 3-adrenoceptor mRNA in rat tissues. Br J Pharmacol 1996;117:210-216.
44. 3-adrenergic receptor mRNA expression in adipose and other metabolic tissues in the adult human. Mol Pharmacol 1993;43:343-348.
45. 3-Adrenoceptor. London & New York: Taylor & Francis, 2000;1-19.
46. 3-adrenoceptor studies using a monoclonal antibody. Int J Obesity 1999;23:1057-1065.
47. 3-adrenergic receptor mRNA by sympathetic nerves and glucocorticoids in BAT of Zucker obese rats. Am J Physiol 1995;269:R519-R526.
48. Macdonald IA. Advances in our understanding of the role of the sympathetic nervous system in obesity. Int J Obes Relat Metab Disord 1995;19:S2-S7.
49. Hollenga C, Zaagsma J. Direct evidence for the atypical nature of functional β-adrenoceptors in rat adipocytes. Br J Pharmacol 1989;98:1420-1424.
50. Hoffstedt J, Lonnqvist F, Shimizu M, Black E, Arner P. Effects of several putative β-adrenoceptor agonists on lipolysis in human omental adipocytes. Int J Obesity 1996;20:428-434.
51. Challis RAJ, Leighton B, Wilson S, Thurlby PL, Arch JRS. An investigation of the β-adrenoceptor that mediates metabolic responses to the novel agonist BRL 28410 in rat soleus muscle. Biochem Pharmacol 1988;37:947-950.
52. 3 adrenergic receptor with body mass index. Int J Obesity 1998;22: 559-566.
53. 3-adrenergic receptor gene with body mass index. J Clin Endocrinol Metab 1998;83:2441-2444.
54. 3-adrenoceptor agonist in human omental adipocytes. Diabetes 1999;48:117-120.
55. 3-adrenergic receptors. Fundament Clin Pharmacol 1995;9:211-218.
56. 3-adrenoceptors mediate metabolic responses to isoprenaline. Quart J Med 1993;86:595-600.
57. 3-adrenoceptor activation to ephedrine-induced thermogenesis in humans. Int J Obesity 1995;19:678-685.
58. Wheeldon NM, McDevitt DG, McFarlane LC, Lipworth BJ. β-adrenoceptor subtypes mediating the metabolic effects of BRL 35135 in man. Clin Sci 1994;86:331-337.
59. 3-adrenergic stimulation of human thermogenesis and lipid use. Clin Pharm Ther 2000;67:558-566.
60. 3-adrenoceptor agonist, in obese men. Obesity Res 2000;8:91S.
61. 3-adrenoceptor depends on receptor expression level and nature of the assay. J Pharmacol Exp Ther 1996;279:214-221.
62. 3-adrenoceptors in tissues. Pharmacol Commun 1995;6(1-3):223-228.
63. Arch JRS, Bywater RJ, Coney KA, Ellis RDM, Thurlby PL, Smith SA, Zed C. β-adrenoceptor-mediated control of thermogenesis, body composition and glucose homeostasis. In: Lardy H, Stratman F, eds. Hormones, Thermogenesis and Obesity. Amsterdam: Elsevier Science Publishing Co., 1995;465-476.
64. Abraham R, Zed C, Mitchell T, Parr J, Wynn V. The effect of a novel β-agonist BRL 26830A on weight and protein loss in obese patients. Int J Obesity 1987;11:306A.
65. Durrant ML, Garrow JS, Royston P, Stalley SF, Sunkin S, Warwick PM. Factors influencing the composition of the weight lost by obese patients on a reducing diet. Br J Nutrition 1980;44:275-285.
66. y mice. Biol Pharm Bull 1999;22:1073-1078.
67. Bryson JM, Wensley VR, Phuyal JL, Caterson ID, Cooney GJ. Chronic administration of BRL 26830A for 9 weeks improves insulin sensitivity but does not prevent weight gain in gold-thioglucose obese mice. Horm Metab Res 1999;31:317-322.
68. Hansen BC. Primates in the experimental pharmacology of obesity. In: Lockwood D, Heffner TG, eds. Handbook of Experimental Pharmacology. 149 edn. Heidelberg: Springer-Verlag, 2000;461-489.
69. Smith SA, Sennitt MV, Cawthorne MA. BRL 35135: an orally active antihyperglycaemic agent with weight reducing effects. In: Bailey CJ, Flatt PR eds. New Antidiabetic Drugs. London: Smith-Gordon, 1990;177-189.
70. 3-adrenoceptor agonist in humans. Diabetes 1998;47:1555-1561.
71. Laybutt DR, Schmitz-peiffer C, Saha AK, Ruderman NB, Biden TJ, Kraegen EW. Muscle lipid accumulation and protein kinase C activation in the insulin-resistant chronically glucose-infused rat. Am J Physiol 1999;277:E1070-E1076.